Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $3.53M | $2.76M | $2.64M | $33.5M |
| Revenue growth | — | — | — | -21.9% | -4.4% | 1169.2% |
| Operating income | — | -$395K | -$32.7M | -$51.5M | -$64.3M | -$51.8M |
| Operating margin | — | — | -924.3% | -1866.2% | -2437.5% | -154.7% |
| Net income | — | -$379K | -$33.6M | -$49.1M | -$61.0M | -$52.7M |
| Net margin | — | — | -951.3% | -1779.7% | -2313.3% | -157.4% |
| EPS (diluted) | — | -$0.02 | -$2.24 | -$1.48 | -$1.66 | -$1.11 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | — | -$272K | -$29.3M | -$46.1M | -$50.6M | -$49.0M |
| Capital expenditures | — | — | $591K | $78.0K | $289K | $489K |
| Free cash flow | — | — | -$29.9M | -$46.2M | -$50.8M | -$49.5M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.03M | $1.75M | $19.8M | $30.6M | $22.3M | $34.7M |
| Total assets | $162M | $162M | $95.6M | $95.2M | $76.2M | $115M |
| Total liabilities | $5.72M | $5.77M | $43.0M | $27.2M | $43.2M | $51.5M |
| Long-term debt | — | — | — | — | $15.0M | $15.0M |
| Shareholders' equity | -$3.56M | -$19.8M | $52.5M | $68.0M | $33.0M | $53.6M |
| Retained earnings | -$3.56M | -$3.94M | -$200M | -$249M | -$310M | -$363M |
| Shares (wtd avg diluted) | 4.45M | 20.4M | 15.0M | 33.2M | 36.8M | 47.7M |
Every figure is extracted from Orchestra BioMed Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.